Literature DB >> 11714276

Removal of the pro-domain does not affect the conformation of the procaspase-3 dimer.

C Pop1, Y R Chen, B Smith, K Bose, B Bobay, A Tripathy, S Franzen, A C Clark.   

Abstract

We have investigated the oligomeric properties of procaspase-3 and a mutant that lacks the pro-domain (called pro-less variant). In addition, we have examined the interactions of the 28 amino acid pro-peptide when added in trans to the pro-less variant. By sedimentation equilibrium studies, we have found that procapase-3 is a stable dimer in solution at 25 degrees C and pH 7.2, and we estimate an upper limit for the equilibrium dissociation constant of approximately 50 nM. Considering the expression levels of caspase-3 in Jurkat cells, we predict that procaspase-3 exists as a dimer in vivo. The pro-less variant is also a dimer, with little apparent change in the equilibrium dissociation constant. Thus, in contrast with the long pro-domain caspases, the pro-peptide of caspase-3 does not appear to be involved in dimerization. Results from circular dichroism, fluorescence anisotropy, and FTIR studies demonstrate that the pro-domain interacts weakly with the pro-less variant. The data suggest that the pro-peptide adopts a beta-structure when in contact with the protein, but it is a random coil when free in solution. In addition, when added in trans, the pro-peptide does not inhibit the activity of the mature caspase-3 heterotetramer. On the other hand, the active caspase-3 does not efficiently hydrolyze the pro-domain at the NSVD(9) sequence as occurs when the pro-peptide is in cis to the protease domain. Based on these results, we propose a model for maturation of the procaspase-3 dimer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714276     DOI: 10.1021/bi011037e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  Caspase-9 holoenzyme is a specific and optimal procaspase-3 processing machine.

Authors:  Qian Yin; Hyun Ho Park; Jee Y Chung; Su-Chang Lin; Yu-Chih Lo; Li S da Graca; Xuejun Jiang; Hao Wu
Journal:  Mol Cell       Date:  2006-04-21       Impact factor: 17.970

2.  Mutations in the procaspase-3 dimer interface affect the activity of the zymogen.

Authors:  Cristina Pop; Brett Feeney; Ashutosh Tripathy; A Clay Clark
Journal:  Biochemistry       Date:  2003-10-28       Impact factor: 3.162

Review 3.  The protein structures that shape caspase activity, specificity, activation and inhibition.

Authors:  Pablo Fuentes-Prior; Guy S Salvesen
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

4.  Novel protein purification system utilizing an N-terminal fusion protein and a caspase-3 cleavable linker.

Authors:  Brett Feeney; Erik J Soderblom; Michael B Goshe; A Clay Clark
Journal:  Protein Expr Purif       Date:  2005-10-27       Impact factor: 1.650

5.  Gene polymorphism linked to increased asthma and IBD risk alters gasdermin-B structure, a sulfatide and phosphoinositide binding protein.

Authors:  Kinlin L Chao; Liudmila Kulakova; Osnat Herzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-01       Impact factor: 11.205

6.  Folding and assembly kinetics of procaspase-3.

Authors:  Sara L Milam; A Clay Clark
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

7.  Reassembly of active caspase-3 is facilitated by the propeptide.

Authors:  Brett Feeney; A Clay Clark
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

8.  A designed redox-controlled caspase.

Authors:  Witold A Witkowski; Jeanne A Hardy
Journal:  Protein Sci       Date:  2011-08       Impact factor: 6.725

9.  pH effects on the stability and dimerization of procaspase-3.

Authors:  Kakoli Bose; A Clay Clark
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

10.  Role of loop bundle hydrogen bonds in the maturation and activity of (Pro)caspase-3.

Authors:  Brett Feeney; Cristina Pop; Paul Swartz; Carla Mattos; A Clay Clark
Journal:  Biochemistry       Date:  2006-11-07       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.